Novel tyrosine kinase inhibitors

A compound according to formula I

• its enantiomers, diastereomers, pharmaceutically acceptable salts, hydrates, prodrugs and solvates thereof:
• wherein
• X is selected from the group consisting of N, C, C1-C3 alkyl, C1-C3 alkyl substituted with one or more R7, and a direct bond;
• Y is selected from the group consisting of O and S;
• W is selected from the group consisting of N, C, O, and S;
• provided that if W is O or S, R9 is absent;
• R1, R2, R3, R4, R5, R6, R7, R8, R9 are each independently selected from the group consisting of H, C1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halo, amino, —OR60, —NO2, —OH, —SR60, —NR60R61, —CN, —CO2R60, —CONR60R61, OCONR60R61, —NR62CONR60R61, —NR60SO2R61, —SO2N R60R61, —SO2R63,
• —C(NR62)NR60R61, aryl, heteroaryl, —(CH2)nOR60, —(CH2)nNR60R61, —(CH2)nSR60,
• —(CH2)n aryl, —(CH2)n heteroaryl, —(CH2)n heterocycloalkyl, —NH-Z-aryl, and —NH-Z-heteroaryl;
• wherein n is 1 to 3;
• and
• Z is selected from the group consisting of C1-C4 alkyl, alkenyl, and alkynyl chain;
• Z having one or more hydroxy, thiol, alkoxy, thioalkoxy, amino, halo, NR60SO2R61 groups;
• Z optionally incorporating one or more groups selected from the group consisting of CO, CNOH, CNOR60, CNNR60, CNNCOR60 and CNNSO2R60;
• and
• R3 is piperazinyl or substituted piperazinyl,
• R60, R61, R62, and R63 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, hydroxy, alkoxy, aryl, heteroaryl, heteroarylalkyl, and alkyl-R25;
• R25 is hydrogen, alkenyl, hydroxy, thiol, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, aryl, heteroaryl, cyano, halo, sulfoxy, sulfonyl, —NR30COOR31, —NR30C(O)R31, —NR30SO2R31, —C(O)NR30R31, heteroaryl or heterocycloalkyl;
• and
• R30 and R31 are, independently, hydrogen, alkyl, or cycloalkyl.